UPDATE: Achillion Has Received US Patent for ACH-3102, Structurally-Related NS5A Inhibitors

Loading...
Loading...
Achillion Pharmaceuticals, Inc.
ACHN
today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032. "We believe that this key patent grant will provide another important anchor for Achillion's intellectual property portfolio. With the issuance of this patent for our differentiated NS5A inhibitor, ACH-3102, along with the previously granted patent for sovaprevir, our NS3/4A protease inhibitor, we are pleased to recognize the talented Achillion team that discovered and has advanced these compounds into Phase 2 trials evaluating their use in all-oral combination regimens for the treatment of chronic HCV," commented Milind Deshpande, President and Chief Executive Officer of Achillion.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...